GERN | Geron Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.34 - 4.53
52 Week Range	1.6400 - 5.34
Beta	0.46
Implied Volatility	67.35%
IV Rank	2.63%
Day's Volume	6,779,018
Average Volume	9,420,509
Shares Outstanding	602,796,000
Market Cap	2,634,218,520
Sector	Healthcare
Industry	Biotechnology
IPO Date	1996-07-31

Valuation
Profitability
Growth
Health
P/E Ratio	-12.49
Forward P/E Ratio	N/A
EPS	-0.35
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	141
Country	USA
Website	GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

GERN's peers: VKTX, TGTX, XFOR, PDSB, MDGL, ZURA, ENVB, EFTR, IMMX, ELEV, SRPT, HEPA, PTCT, CWBR, OCEA, AVRO, LQDA

*Chart delayed

Analyzing fundamentals for GERN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see GERN Fundamentals page.

Watching at GERN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on GERN Technicals page.